{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:44:54Z","timestamp":1790390694105,"version":"4.1.0"},"reference-count":212,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,5,5]],"date-time":"2015-05-05T00:00:00Z","timestamp":1430784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,5,5]],"date-time":"2015-05-05T00:00:00Z","timestamp":1430784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s12072-015-9630-4","type":"journal-article","created":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T10:48:21Z","timestamp":1430736501000},"page":"486-507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries"],"prefix":"10.1007","volume":"9","author":[{"given":"Masao","family":"Omata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Yokosuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamun","family":"Al-Mahtab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaaeldin","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George K. K.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barjesh C.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed S.","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Kadir","family":"Dokmeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,5]]},"reference":[{"issue":"1 Suppl","key":"9630_CR1","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","volume":"61","author":"RH Westbrook","year":"2014","unstructured":"Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61(1 Suppl):S58\u2013S68","journal-title":"J Hepatol"},{"key":"9630_CR2","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.1073\/pnas.87.17.6547","volume":"87","author":"I Saito","year":"1990","unstructured":"Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA. 1990;87:6547\u20136549","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 2","key":"9630_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1478-3231.2011.02540.x","volume":"31","author":"W Sievert","year":"2011","unstructured":"Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31(Suppl 2):61\u201380","journal-title":"Liver Int"},{"key":"9630_CR4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s12072-010-9193-3","volume":"4","author":"T Kanda","year":"2010","unstructured":"Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int 2010;4:548\u2013561","journal-title":"Hepatol Int"},{"key":"9630_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"YF Liaw","year":"2012","unstructured":"Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531\u2013561","journal-title":"Hepatol Int"},{"key":"9630_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1478-3231.2005.01196.x","volume":"26","author":"ML Yu","year":"2006","unstructured":"Yu ML, Dai CY, Lin ZY, Lee LP, Hou NJ, Hsieh MY, et al. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int 2006;26:73\u201381","journal-title":"Liver Int"},{"key":"9630_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jhep.2011.07.016","volume":"56","author":"H Kumada","year":"2012","unstructured":"Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012;56:78\u201384","journal-title":"J Hepatol"},{"key":"9630_CR8","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/jvh.12312","volume":"21","author":"M Omata","year":"2014","unstructured":"Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 2014;21:762\u2013768","journal-title":"J Viral Hepat"},{"key":"9630_CR9","doi-asserted-by":"crossref","unstructured":"Ferenci P, Asselah T, Foster GR, Zeuzem S, Sarrazin C, Moreno C, et al. STARTVerso1: a randomized trial of faldaprevir plus pegylated interferon\/ribavirin for chronic HCV genotype-1 infection. J Hepatol 2015 Jan 2 (in press)","DOI":"10.1016\/j.jhep.2014.12.024"},{"key":"9630_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S1386-6532(02)00116-6","volume":"26","author":"GJ Dore","year":"2003","unstructured":"Dore GJ, Law G, MacDonald M, Kaldor JM. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003;26:171\u2013184","journal-title":"J Clin Virol"},{"key":"9630_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2217\/17460913.1.1.103","volume":"1","author":"DS Bowden","year":"2006","unstructured":"Bowden DS, Berzsenyi MD. Chronic hepatitis C virus infection; genotyping and its clinical role. Future Microbiol 2006;1:103\u2013112","journal-title":"Future Microbiol"},{"key":"9630_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/jgh.12424","volume":"29","author":"SK Roberts","year":"2014","unstructured":"Roberts SK, Mitchell J, Leung R, Booth D, Bollipo S, Ostapowicz G, et al. Distribution of interferon lamda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: analysis from the PREDICT and CHARIOT studies. J Gastroenterol Hepatol 2014;29:179\u2013184","journal-title":"J Gastroenterol Hepatol"},{"key":"9630_CR13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.5694\/j.1326-5377.2003.tb05192.x","volume":"178","author":"D Kumar","year":"2003","unstructured":"Kumar D, Wallington-Beddoe C, George J, Lin R, Samarasinghe D, Liddle C, et al. Effectiveness of intereferon alfa-2b\/ribavirin combination therapy for chronic hepatitis C in a clinic setting. Med J Aust 2003;178:267\u2013271","journal-title":"Med J Aust"},{"key":"9630_CR14","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/hep.23130","volume":"50","author":"SK Roberts","year":"2009","unstructured":"Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, et al. Impact of high dose peginterferon alpha-2A on virological response rates in hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2009;50:1045\u20131055","journal-title":"Hepatology"},{"key":"9630_CR15","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405\u20132410","journal-title":"N Engl J Med"},{"key":"9630_CR16","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Bocepravir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195\u2013206","journal-title":"N Engl J Med"},{"key":"9630_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/BF02989200","volume":"28","author":"M Khan","year":"1993","unstructured":"Khan M, Husain M, Yano M, Hashizume K, Yousuf M, Tanaka E, et al. Comparison of seroepidemiology of hepatitis C in blood donors between Bangladesh and Japan. Gastroenterol Jpn. 1993;28:28\u201331","journal-title":"Gastroenterol Jpn"},{"key":"9630_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0928-4346(97)00027-3","volume":"7","author":"SMF Akbar","year":"1997","unstructured":"Akbar SMF, Hossain M, Hossain MF, Sarker S, Hossain SAS, Tanimoto K, et al. Seroepidemiology of hepatitis viruses of chronic liver diseases in Bangladesh: high prevalence of HCV among blood donors and healthy persons. Hepatol Res. 1997;7:113\u2013120","journal-title":"Hepatol Res"},{"key":"9630_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0973-6883(11)60111-4","volume":"1","author":"MA Mahtab","year":"2011","unstructured":"Mahtab MA, Karim F, Foster G, Akbar SMF, Rahman S. Prevalence and risk factors of asymptomatic HCV infection in Bangladesh. J Clin Exp Hepatol 2011;1:13\u201316","journal-title":"J Clin Exp Hepatol"},{"key":"9630_CR20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/1471-2334-10-208","volume":"10","author":"H Ashraf","year":"2010","unstructured":"Ashraf H, Alam NH, Rothermundt C, Brooks A, Bardhan P, Hossain L, et al. Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. BMC Infect Dis 2010;10:208","journal-title":"BMC Infect Dis"},{"key":"9630_CR21","first-page":"183","volume":"20","author":"S Rudra","year":"2011","unstructured":"Rudra S, Chakrabarty P, Poddar B. Prevalence of hepatitis B and hepatitis C virus infection in human of Mymensingh, Bangladesh. Mymensingh Med J 2011;20:183\u2013186","journal-title":"Mymensingh Med J"},{"key":"9630_CR22","first-page":"515","volume":"19","author":"S Rudra","year":"2010","unstructured":"Rudra S, Chakrabarty P, Hossain MA, Akhter H, Bhuiyan MR. Seroprevalence of Hepatitis B, Hepatitis C, HIV Infections in blood donors of Khulna, Bangladesh. Mymensingh Med J 2010;19:515\u2013519","journal-title":"Mymensingh Med J"},{"key":"9630_CR23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.gaceta.2009.10.013","volume":"24","author":"MRM Aliberch","year":"2010","unstructured":"Aliberch MRM, Bux\u00f3 AE, Gil BM, Rodriguez CC, de FrutosGallego E, Molina CG, et al. Indication of determination of antibodies against hepatitis C and A viruses in the protocol for the care of young immigrants. Gac Sanit 2010;24:288\u2013292","journal-title":"Gac Sanit"},{"key":"9630_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1365-2893.2009.01240.x","volume":"17","author":"G Uddin","year":"2010","unstructured":"Uddin G, Shoeb D, Solaiman S, Marley R, Gore C, Ramsay M, et al. Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepat 2010;17:327\u2013335","journal-title":"J Viral Hepat"},{"key":"9630_CR25","first-page":"145","volume":"18","author":"T Shirin","year":"2000","unstructured":"Shirin T, Ahmed T, Iqbal A, Islam M, Islam MN. Prevalence and risk factors of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections among drug addicts in Bangladesh. J Health Popul Nutr 2000;18:145\u2013150","journal-title":"J Health Popul Nutr"},{"key":"9630_CR26","first-page":"235","volume":"23","author":"P Chakrabarty","year":"2014","unstructured":"Chakrabarty P, Rudra S, Hossain MA. Prevalence of HBV and HCV among the multi-transfused beta thalassemic major patients in a Day Care Centre of Blood Transfusion Department of Mymensingh Medical College Hospital. Mymensingh Med J 2014;23:235\u2013241","journal-title":"Mymensingh Med J"},{"key":"9630_CR27","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.3748\/wjg.15.5647","volume":"15","author":"Y Waheed","year":"2009","unstructured":"Waheed Y, Shafi T, Safi SZ, Qadri I. HCV in Pakistani: a systematic review of prevalence genotypes and risk factors. World J Gastroenterol 2009;15:5647\u20135653","journal-title":"World J Gastroenterol"},{"key":"9630_CR28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/1743-422X-8-211","volume":"8","author":"Y Waheed","year":"2011","unstructured":"Waheed Y, Safi SZ, Qadri I. Role of potash alum in hepatitis C virus transmission at barber\u2019s shop. Virol J 2011;8:211","journal-title":"Virol J"},{"key":"9630_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1556\/HMJ.2.2008.4.9","volume":"2","author":"MA Mahtab","year":"2008","unstructured":"Mahtab MA, Rahman S, Khan M, Karim F, Sharif NM, Shrestha A. Genotypes of HCV in Bangladesh: experience from a tertiary cenrtre. Hungarian Med J 2008;2:577\u2013581","journal-title":"Hungarian Med J"},{"issue":"Suppl","key":"9630_CR30","first-page":"27","volume":"23","author":"MA Mahtab","year":"2008","unstructured":"Mahtab MA, Rahman S, Karim MF, Khan M. Genotypes of HCV in Bangladesh: experience from a tertiary centre. J Gastroenterol Hepatol 2008;23(Suppl):27\u201328","journal-title":"J Gastroenterol Hepatol"},{"key":"9630_CR31","unstructured":"Islam ASM. Thesis submitted to Bangabandhu Sheiikh Mujib Medical University for fulfillment of Doctor of Medicine in Hepatology 2014"},{"key":"9630_CR32","first-page":"335","volume":"23","author":"MZ Rahman","year":"2014","unstructured":"Rahman MZ, Perveen S, Mahmuduzzaman M, Rahman MA, Chowdhury MS, Huda MN, et al. Peginterferon \u03b1-2a and Rivabirin in the Treatment of Chronic Hepatitis C. Mymensingh Med J 2014;23:335\u2013340","journal-title":"Mymensingh Med J"},{"key":"9630_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3329\/bmrcb.v39i1.15791","volume":"39","author":"MZ Rahman","year":"2013","unstructured":"Rahman MZ, Ahmed DS, Masud H, Parveen S, Rahman MA, Chowdhury MS, et al. Sustained virological response after treatment in patients with chronic hepatitis C infection\u2014a five year follow up. Bangladesh Med Res Counc Bull 2013;39:11\u201313","journal-title":"Bangladesh Med Res Counc Bull"},{"key":"9630_CR34","unstructured":"National Statistics Bureau, China. http:\/\/www.gov.cn\/test\/2012-04\/20\/content_2118413.htm. Accessed on 30 Mar 2014"},{"key":"9630_CR35","first-page":"60","volume-title":"The Seroprevalence Survey of Virus Hepatitis in China, 1992\u20131995","author":"ZC Dai","year":"1995","unstructured":"Dai ZC, Qi GM. The Seroprevalence Survey of Virus Hepatitis in China, 1992\u20131995. Beijing: Scientific and Technical Literature Publishers; 1995: 60\u201371"},{"issue":"9","key":"9630_CR36","first-page":"888","volume":"32","author":"YS Chen","year":"2011","unstructured":"Chen YS, Li L, Cui FQ, Xing WG, Wang L, Jia ZY, et al. A sero-epidemiological study on hepatitis C in China. Chin J Epidemiol (in Chinese) 2011;32(9):888\u2013891","journal-title":"Chin J Epidemiol (in Chinese)"},{"issue":"2","key":"9630_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","volume":"17","author":"D Lavanchy","year":"2011","unstructured":"Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17(2):107\u2013115","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"9630_CR38","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1128\/JCM.00273-12","volume":"50","author":"WP Lu","year":"2012","unstructured":"Lu WP, Lin GX, Shi S, Dong JH. Simultaneously high prevalences of hepatitis B and C virus infections in a population in Putian County, China. J Clin Microbiol 2012;50(6):2142\u20132144","journal-title":"J Clin Microbiol"},{"issue":"3","key":"9630_CR39","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/jgh.12398","volume":"29","author":"H Rao","year":"2014","unstructured":"Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2014;29(3):545\u2013553","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"9630_CR40","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/j.1440-1746.2007.04904.x","volume":"22","author":"JW Yu","year":"2007","unstructured":"Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007;22(6):832\u2013836","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"9630_CR41","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/j.1742-1241.2009.02082.x","volume":"63","author":"SH Zhao","year":"2009","unstructured":"Zhao SH, Chu YL, Cheng DX, Waqar AB, Yu Q, Yang PH, et al. Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48\u00a0weeks in Chinese patients with chronic hepatitis C. Int J Clin Pract 2009;63(9):1334\u20131339","journal-title":"Int J Clin Pract"},{"issue":"5","key":"9630_CR42","first-page":"353","volume":"20","author":"QR Li","year":"2012","unstructured":"Li QR, Zhang CJ, Xiong YL, Zhu Y, Tan ZX, Hu YJ, et al. Long-term assessment of relapse and associated risk factors in chronic hepatitis C patients treated with interferon and ribavirin. Zhonghua Gan Zang Bing Za Zhi (in Chinese) 2012;20(5):353\u2013356","journal-title":"Zhonghua Gan Zang Bing Za Zhi (in Chinese)"},{"issue":"8","key":"9630_CR43","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1365-2893.2010.01373.x","volume":"18","author":"YQ Zhou","year":"2011","unstructured":"Zhou YQ, Wang XH, Hong GH, Zhu Y, Zhang XQ, Hu YJ, et al. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a. J Viral Hepat 2011;18(8):595\u2013600","journal-title":"J Viral Hepat"},{"key":"9630_CR44","unstructured":"ClinicalTrials.gov. An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients. NCT01725529. http:\/\/clinicaltrials.gov\/ct2\/results?term=NCT01725529&Search=Search. Accessed on 27 Oct 2014"},{"key":"9630_CR45","unstructured":"ClinicalTrials.gov. Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual. NCT01995266. http:\/\/clinicaltrials.gov\/ct2\/results?term=NCT01995266&Search=Search. Accessed on 1 July 2014"},{"key":"9630_CR46","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/j.1365-2893.2011.01576.x","volume":"19","author":"J Guerra","year":"2012","unstructured":"Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 2012;19:560\u2013567","journal-title":"J Viral Hepat"},{"key":"9630_CR47","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jcv.2013.01.005","volume":"57","author":"SF Abdelwahab","year":"2013","unstructured":"Abdelwahab SF, Hashem M, Galal I, Sobhy M, Abdel-Ghaffar TS, Galal G, et al. Incidence of hepatitis C virus infection among Egyptian healthcare workers at high risk of infection. J Clin Virol 2013;57:24\u201328","journal-title":"J Clin Virol"},{"key":"9630_CR48","unstructured":"El-Zanaty F, Way A. Egypt Demographic and Health Survey. 2008. Ministry of Health, El-Zanaty and Associates, and Macro International, accessed at http:\/\/www.measuredhs.com, Cairo, Egypt"},{"key":"9630_CR49","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/molbev\/msg043","volume":"20","author":"OG Pybus","year":"2003","unstructured":"Pybus OG, Drummond AJ, Nakano T, Robertson BH, Rambaut A. The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. Mol Biol Evol 2003;20:381\u2013387","journal-title":"Mol Biol Evol"},{"key":"9630_CR50","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.trstmh.2011.10.003","volume":"106","author":"S Abdelwahab","year":"2012","unstructured":"Abdelwahab S, Rewisha E, Hashem M, Sobhy M, Galal I, Allam WR, et al. Risk factors for hepatitis C virus infection among Egyptian healthcare workers in a national liver diseases referral centre. Trans R Soc Trop Med Hyg 2012;106:98\u2013103","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"9630_CR51","doi-asserted-by":"publisher","first-page":"e101264","DOI":"10.1371\/journal.pone.0101264","volume":"9","author":"IF Galal","year":"2014","unstructured":"Galal IF, Zakaria Z, Allam W, Mahmoud MA, Ezzat AR, Osman A, et al. Cross reactive cellular immune response to HCV Genotype 1 and 4 Antigens among Genotype 4 exposed subjects. PLoS One 2014;9:e101264","journal-title":"PLoS One"},{"key":"9630_CR52","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.jhep.2010.11.016","volume":"54","author":"MA Khattab","year":"2011","unstructured":"Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011;54:1250\u20131262","journal-title":"J Hepatol"},{"key":"9630_CR53","doi-asserted-by":"publisher","first-page":"111","DOI":"10.7869\/tg.2012.27","volume":"33","author":"HR El Khayat","year":"2012","unstructured":"El Khayat HR, Fouad YM, El Amin H, Rizk A. A randomized trial of 24 versus 48\u00a0weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response. Trop Gastroenterol 2012;33:111\u2013112","journal-title":"Trop Gastroenterol"},{"key":"9630_CR54","first-page":"141","volume":"33 Suppl","author":"G Esmat","year":"2013","unstructured":"Esmat G, El Kassas M, Hassany M, Gamil ME, El Raziky M. How to optimize HCV therapy in genotype 4 patients. Liver Int 2013;33 Suppl:141\u2013145","journal-title":"Liver Int"},{"key":"9630_CR55","unstructured":"El-Zanaty F, Way A. Egypt Demographic and Health Survey, 2008. Cairo: Ministry of Health, El-Zanaty and Associates, and Macro International; 2009. http:\/\/www.measuredhs.com"},{"key":"9630_CR56","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/jvh.12248","volume":"Suppl 1","author":"H Razavi","year":"2014","unstructured":"Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today\u2019s treatment paradigm. J Viral Hepat 2014;Suppl 1:34\u201359","journal-title":"J Viral Hepat"},{"key":"9630_CR57","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/1471-2334-13-288","volume":"13","author":"YA Mohamoud","year":"2013","unstructured":"Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013;13:288","journal-title":"BMC Infect Dis"},{"key":"9630_CR58","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12617","author":"EM El-Ghitany","year":"2014","unstructured":"El-Ghitany EM, Abdel Wahab MM, Abd El-Wahab EW, Hassouna S, Farghaly AG. A comprehensive hepatitis C virus risk factors meta-analysis (1989\u20132013); Do they differ in Egypt? Liver Int 2014 Jun 12;. doi:10.1111\/liv.12617","journal-title":"Liver Int"},{"key":"9630_CR59","doi-asserted-by":"crossref","unstructured":"Recker C, Islam KM. Risk factors associated with high prevalence rates of hepatitis C infection in Egypt. Int J Infect Dis 2014","DOI":"10.1016\/j.ijid.2014.02.003"},{"key":"9630_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27248","author":"DF Cuadros","year":"2014","unstructured":"Cuadros DF, Branscum AJ, Miller FD, Abu-Raddad LJ. Spatial epidemiology of hepatitis C virus infection in Egypt: analyses and implications. Hepatology 2014;. doi:10.1002\/hep.27248","journal-title":"Hepatology"},{"key":"9630_CR61","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878\u20131887","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"9630_CR62","doi-asserted-by":"publisher","first-page":"S503","DOI":"10.1016\/S0168-8278(14)61403-3","volume":"60","author":"PJ Ruane","year":"2014","unstructured":"Ruane PJ, Ain D, Meshrekey R, Riad J, Soliman M, Mikhail S, et al. Sofosbuvir plus ribavirin, an interferon-free regimen, in the treatment of treatment-naive and treatment-experienced patients with chronic genotype 4 HCV infection. J Hepatol 2014;60(suppl 1):S503\u2013S504","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"9630_CR63","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/S0168-8278(14)60060-X","volume":"60","author":"C Hezode","year":"2014","unstructured":"Hezode C, Marcellin P, Pol S, Hassanein T, Fleischer-Stepniewska K, Baykal T, et al. Results from the phase 2 PEARL-I Study: interferon-free regimens of ABT-450\/R+ ABT-267 with or without ribavirin in patients with HCV genotype 4 infection. J Hepatol 2014;60(suppl 1):S24","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"9630_CR64","doi-asserted-by":"publisher","first-page":"S472","DOI":"10.1016\/S0168-8278(14)61323-4","volume":"60","author":"T Hassanein","year":"2014","unstructured":"Hassanein T, Sims K, Bennett M, Gitlin N, Lawitz E, Nguyen T, et al. All-oral therapy with daclatasvir in combination with asunaprevir and BMS-791325 for treatment-na\u00efve patients with chronic HCV genotype 4 infection. J Hepatol 2014;60(suppl 1):S472","journal-title":"J Hepatol"},{"key":"9630_CR65","unstructured":"Tourism Commisson. Commerce and Economic Development Bureau. The Government of the Hong Kong Special Administrative Region. Tourism Performance. http:\/\/www.tourism.gov.hk\/english\/statistics\/statistics_perform.html. Accessed on 27 Oct 2014"},{"issue":"2","key":"9630_CR66","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1365-3148.2011.01128.x","volume":"22","author":"HK Wong","year":"2012","unstructured":"Wong HK, Lee CK, Leung JN, Tsoi WC, Lin CK. Risk factor analysis of hepatitis C virus infection among Chinese blood donors in Hong Kong. Transfus Med 2012;22(2):133\u2013136","journal-title":"Transfus Med"},{"key":"9630_CR67","unstructured":"Oi Y, Cheng T, Si-Yuan. Hepatitis free generation liver clinic. https:\/\/www.facebook.com\/media\/set\/?set=a.347366178676981.82177.331213273625605&type=3. Accessed on 27 Oct 2014"},{"issue":"1","key":"9630_CR68","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/jgh.12355","volume":"29","author":"VW Wong","year":"2014","unstructured":"Wong VW, Wong GL, Chim AM, Cheng TF, Cheung SW, Lai CM, et al. Targeted hepatitis C screening among ex-injection drug users in the community. J Gastroenterol Hepatol 2014;29(1):116\u2013120","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"9630_CR69","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jhep.2010.04.009","volume":"53","author":"WK Seto","year":"2010","unstructured":"Seto WK, Lai CL, Fung J, Hung I, Yuen J, Young J, et al. Natural history of chronic hepatitis C: genotype 1 versus genotype 6. J Hepatol 2010;53(3):444\u2013448","journal-title":"J Hepatol"},{"issue":"6","key":"9630_CR70","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1086\/591252","volume":"198","author":"J Fung","year":"2008","unstructured":"Fung J, Lai CL, Hung I, Young J, Cheng C, Wong D, et al. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008;198(6):808\u2013812","journal-title":"J Infect Dis"},{"key":"9630_CR71","unstructured":"\u201cCensus of India Website: Office of the Registrar General and Census Commissioner, India\u201d Censusindia.gov.in. Retrieved 2011-09-26"},{"key":"9630_CR72","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jceh.2014.05.006","volume":"4","author":"P Puri","year":"2014","unstructured":"Puri P, Anand AC, Saraswat VA, Acharya SK, Dhiman RK, Aggarwal R, et al. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India. J Clin Exp Hepatol 2014;4:106\u2013116","journal-title":"J Clin Exp Hepatol"},{"key":"9630_CR73","first-page":"255","volume":"58","author":"N Gupta","year":"2004","unstructured":"Gupta N, Kumar V, Kaur A. Seroprevalence of HIV, HBV, HCV and syphilis in voluntary blood donors. Indian J Med Sci 2004;58:255\u2013257","journal-title":"Indian J Med Sci"},{"key":"9630_CR74","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1097\/00042737-199911000-00008","volume":"11","author":"A Jain","year":"1999","unstructured":"Jain A, Kar P, Madan K, Das UP, Budhiraja S, Gopalkrishna V, et al. Hepatitis C virus infection in sporadic fulminant viral hepatitis in North India: cause or cofactor? Eur J Gastroenterol Hepatol. 1999;11:1231\u20131237","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"9630_CR75","first-page":"323","volume":"45","author":"BR Das","year":"2002","unstructured":"Das BR, Kundu B, Khandapkar R, Sahni S. Geographical distribution of hepatitis C virus genotypes in India. Indian J Pathol Microbiol 2002;45:323\u2013328","journal-title":"Indian J Pathol Microbiol"},{"issue":"465","key":"9630_CR76","first-page":"473","volume":"33","author":"A Mukhopadhya","year":"2008","unstructured":"Mukhopadhya A. Hepatitis C in India. J Biosci 2008;33(465):473","journal-title":"J Biosci"},{"key":"9630_CR77","first-page":"64","volume":"19","author":"D Kapoor","year":"2000","unstructured":"Kapoor D, Saxena R, Sood B, Sarin SK. Blood transfusion practices in India: results of a national survey. Indian J Gastroenteral 2000;19:64\u201367","journal-title":"Indian J Gastroenteral"},{"key":"9630_CR78","first-page":"430","volume":"94","author":"DK Bhattacharya","year":"1991","unstructured":"Bhattacharya DK, Bhattacharjee S, De M, Lahiri P. Prevalence ofhepatitis C in transfusion dependent thalassaemics & haemophilics. Indian J Med Res. 1991;94:430\u2013432","journal-title":"Indian J Med Res"},{"key":"9630_CR79","first-page":"80","volume":"11","author":"DN Amarapurkar","year":"1992","unstructured":"Amarapurkar DN, Kumar A, Vaidya S, et al. Frequency of hepatitis B, C and D and human immunodeficiency virus infections in multitransfused thalassemics. Indian J Gastroenterol. 1992;11:80\u201381","journal-title":"Indian J Gastroenterol"},{"key":"9630_CR80","first-page":"1119","volume":"29","author":"TN Williams","year":"1992","unstructured":"Williams TN, Wonke B, Donohue SM. A study of hepatitis B and C prevalence and liver function in multiply transfused thalassemic and their parents. Indian Pediatr. 1992;29:1119\u20131124","journal-title":"Indian Pediatr"},{"key":"9630_CR81","first-page":"195","volume":"41","author":"MB Agarwal","year":"1993","unstructured":"Agarwal MB, Malkan GH, Bhave AA, Vishwanathan C, Billa V, Dube SR, et al. Antibody to hepatitis-C virus in multi-transfused thalassaemics-Indian experience. J Assoc Physicians India. 1993;41:195\u2013197","journal-title":"J Assoc Physicians India"},{"key":"9630_CR82","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/BF02825110","volume":"62","author":"VP Choudhry","year":"1995","unstructured":"Choudhry VP, Acharya SK. Hepatitis B, C & D viral markers in multitransfuse thalassemic children: long-term complications and present management. Indian J Pediatr. 1995;62:655\u2013668","journal-title":"Indian J Pediatr"},{"key":"9630_CR83","first-page":"37","volume":"111","author":"MK Saha","year":"2000","unstructured":"Saha MK, Chakrabarti S, Panda S, Naik TN, Manna B, Chatterjee A, et al. Prevalence of HCV & HBV infection amongst HIV seropositive intravenous drug users & their non-injecting wives in Manipur, India. Indian J Med Res 2000;111:37\u201339","journal-title":"Indian J Med Res"},{"issue":"suppl 3","key":"9630_CR84","first-page":"10","volume":"82","author":"C Aceijas","year":"2006","unstructured":"Aceijas C, Friedman SR, Cooper HL, Wiessing L, Stimson GV, Hickman M. Estimates of injection drug users at a national andlocal level in developing and translational countries, and gender and age distribution. Sex Transm Infect 2006;82(suppl 3):10\u201317","journal-title":"Sex Transm Infect"},{"key":"9630_CR85","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(03)13006-1","volume":"361","author":"K Sarkar","year":"2003","unstructured":"Sarkar K, Mitra S, Bal B, Chakrabarti S, Bhattacharya SK. Rapidspread of hepatitis C and needle exchange programme in Kolkata, India. Lancet 2003;361:1301\u20131302","journal-title":"Lancet"},{"key":"9630_CR86","first-page":"228","volume":"32","author":"SA Ganju","year":"2000","unstructured":"Ganju SA, Goel A. Prevalence of HBV and HCV infection amonghealth care workers (HCWs). J Commun Dis 2000;32:228\u2013230","journal-title":"J Commun Dis"},{"key":"9630_CR87","first-page":"10","volume":"3","author":"A Kalaskar","year":"2012","unstructured":"Kalaskar A, Kumar M. Prevalence of Hepatitis B and Hepatitis C viruses among nurses and nursing students in a medical collegehospital in southern Tamil Nadu, India. Int Res J Microbiol 2012;3:10\u201313","journal-title":"Int Res J Microbiol"},{"issue":"3","key":"9630_CR88","first-page":"125","volume":"23","author":"A Duseja","year":"2002","unstructured":"Duseja A, Arora L, Masih B, Singh H, Gupta A, Behera D, et al. Hepatitis B and C virus prevalence and prevention in health care workers. Trop Gastoenterol 2002;23(3):125\u2013126","journal-title":"Trop Gastoenterol"},{"key":"9630_CR89","first-page":"179","volume":"123","author":"N Jindal","year":"2006","unstructured":"Jindal N, Jindal M, Jilani N, Kar P. Seroprevalence of hepatis C virus (HCV) in health care workers of tertiary care centre in New Delhi. Indian J Med Res 2006;123:179\u2013180","journal-title":"Indian J Med Res"},{"issue":"1","key":"9630_CR90","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12664-012-0163-7","volume":"31","author":"A Sood","year":"2012","unstructured":"Sood A, Midha V, Bansal M, Sood N, Puri S, Thara A. Perinatal transmission of hepatitis C virus in northern India. Indian J Gastroenterol 2012;31(1):27\u20139. doi:10.1007\/s12664-012-0163-7","journal-title":"Indian J Gastroenterol"},{"key":"9630_CR91","doi-asserted-by":"publisher","first-page":"e394","DOI":"10.1016\/j.ijid.2009.01.013","volume":"13","author":"R Parthiban","year":"2009","unstructured":"Parthiban R, Shanmugam S, Velu V, Nandakumar S, Dhevahi E, Thangaraj K, et al. Transmission of hepatitisC virus from asymptomatic mother to child in southern India. Int J Infect Dis 2009;13:e394\u2013e400","journal-title":"Int J Infect Dis"},{"issue":"suppl l","key":"9630_CR92","first-page":"30","volume":"136","author":"P Barua","year":"2012","unstructured":"Barua P, Mahanta J, Medhi GK, Dale J, Paranjape RS, Thongamba G. Sexual activity as a risk factor for hepatitis C virus (HCV) transmission among female sex workers in Nagaland. Indian J Med Res 2012;136(suppl l):30\u201335","journal-title":"Indian J Med Res"},{"key":"9630_CR93","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1086\/376639","volume":"37","author":"MA Marx","year":"2003","unstructured":"Marx MA, Murugavel KG, Tarwater PM, SriKrishnan AK, Thomas DL, Solomon S, et al. Association of hepatitis C virus infection with sexual exposure in southern India. Clin Infect Dis 2003;37:514\u2013520","journal-title":"Clin Infect Dis"},{"key":"9630_CR94","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10461-010-9711-2","volume":"14","author":"SS Solomon","year":"2010","unstructured":"Solomon SS, Srikrishnan AK, Sifakis F, Mehta SH, Vasudevan CK, Balakrishnan P, et al. The emerging HIVepidemic among men who have sex with men in Tamil Nadu, India: geographic diffusion and bisexual concurrency. AIDS Behav 2010;14:1001\u20131010","journal-title":"AIDS Behav"},{"key":"9630_CR95","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1136\/sti.79.5.424","volume":"79","author":"M Pereira","year":"2003","unstructured":"Pereira M, Tripathy S, Inamdar V, Ramesh K, Bhavsar M, Date A, et al. Lack of evidence for sexualtransmission of hepatitis C virus in patients attending STD clinics in Pune, India. Sex Transm Infect 2003;79:424\u2013429","journal-title":"Sex Transm Infect"},{"key":"9630_CR96","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4103\/0255-0857.16049","volume":"23","author":"AK Reddy","year":"2005","unstructured":"Reddy AK, Murthy KV, Lakshmi V. Prevalence of HCV infection in patients on haemodialysis: survey by antibody and core antigen detection. Indian J Med Microbiol 2005;23:106\u2013110","journal-title":"Indian J Med Microbiol"},{"key":"9630_CR97","first-page":"234","volume":"31","author":"SK Jaiswal","year":"2002","unstructured":"Jaiswal SK, Chitnis DS, Salgia P, Sepaha A, Pandit CS. Prevalenceof hepatitis viruses among chronic renal failure patients on haemodialysisin Central India. Dial Transplant 2002;31:234\u2013240","journal-title":"Dial Transplant"},{"key":"9630_CR98","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jceh.2013.02.003","volume":"3","author":"G Mittal","year":"2013","unstructured":"Mittal G, Gupta P, Thakuria B, Mukhiya GK, Mitta M. Profile of hepatitisB virus, hepatitis C virus, hepatitis d virus and human immunodeficiencyvirus infections in hemodialysis patients of a tertiarycare hospital in Uttarakhand. J Clin Exp Hepatol 2013;3:24\u201328","journal-title":"J Clin Exp Hepatol"},{"key":"9630_CR99","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0955-470X(99)80082-2","volume":"13","author":"GT John","year":"1999","unstructured":"John GT. Infections after renal transplantation in India. Transplant Rev. 1999;13:183\u2013191","journal-title":"Transplant Rev"},{"key":"9630_CR100","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1159\/000080883","volume":"47","author":"M Chandra","year":"2004","unstructured":"Chandra M, Khaja MN, Hussain MM, Poduri CD, Farees N, Habeeb MA, et al. Prevalence of hepatitisB and hepatitis C viral infections in Indian patients with chronicrenal failure. Intervirology 2004;47:374\u2013376","journal-title":"Intervirology"},{"key":"9630_CR101","first-page":"1139","volume":"47","author":"SK Agarwal","year":"1999","unstructured":"Agarwal SK, Dash SC, Irshad M. Hepatitis C virus infection duringhaemodialysis in India. J Assoc Physicians India. 1999;47:1139\u20131143","journal-title":"J Assoc Physicians India"},{"key":"9630_CR102","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4103\/0255-0857.16049","volume":"23","author":"AK Reddy","year":"2005","unstructured":"Reddy AK, Murthy KV, Lakshmi V. Prevalence of HCV infection inpatients on haemodialysis: survey by antibody and core antigendetection. Indian J Med Microbiol 2005;23:106\u2013110","journal-title":"Indian J Med Microbiol"},{"issue":"4","key":"9630_CR103","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.meegid.2009.04.001","volume":"9","author":"S Narahari","year":"2009","unstructured":"Narahari S, Juwle A, Basak S, Saranath D. Prevalence and geographic distribution of hepatitis C virus genotypes in Indian patient cohort. Infect Genet Evol 2009;9(4):643\u2013645","journal-title":"Infect Genet Evol"},{"key":"9630_CR104","first-page":"983","volume":"49","author":"D Amarapurkar","year":"2001","unstructured":"Amarapurkar D, Dhorda M, Kirpalani A, Amarapurkar A, Kankonkar S. Prevalence of hepatitis C genotypes in Indian patients and their clinical significance. J Assoc Physicians India 2001;49:983\u2013985","journal-title":"J Assoc Physicians India"},{"key":"9630_CR105","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12664-009-0018-z","volume":"28","author":"R Abraham","year":"2009","unstructured":"Abraham R, Ramakrishna B, Balekuduru A, Daniel HD, Abraham P, Eapen CE, et al. Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease. Indian J Gastroenterol 2009;28:53\u201358","journal-title":"Indian J Gastroenterol"},{"key":"9630_CR106","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/jmv.20561","volume":"78","author":"SS Hissar","year":"2006","unstructured":"Hissar SS, Goyal A, Kumar M, Pandey C, Suneetha PV, Sood A, et al. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol 2006;78:452\u2013458","journal-title":"J Med Virol"},{"key":"9630_CR107","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1386-6532(02)00025-2","volume":"26","author":"S Raghuraman","year":"2003","unstructured":"Raghuraman S, Shaji RV, Sridharan G, Radhakrishnan S, Chandy G, Ramakrishna BS, et al. Distribution of the different genotypes of HCV among patients attending a tertiary care hospital in south India. J Clin Virol 2003;26:61\u201369","journal-title":"J Clin Virol"},{"key":"9630_CR108","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.meegid.2009.04.001","volume":"9","author":"S Narhari","year":"2009","unstructured":"Narhari S, Juwle A, Basak S, Saranath D. Prevalence and geographic distribution of hepatitis C virus genotypes in Indian patient cohort. Infect Genet Evol 2009;9:643\u2013645","journal-title":"Infect Genet Evol"},{"key":"9630_CR109","first-page":"323","volume":"45","author":"BR Das","year":"2002","unstructured":"Das BR, Kundu B, Khanapkar R, Sahni S. Geographical distribution of hepatitis C virus genotypes in India. Indian J Pathol Microbiol 2002;45:323\u2013328","journal-title":"Indian J Pathol Microbiol"},{"key":"9630_CR110","first-page":"145","volume":"119","author":"S Singh","year":"2004","unstructured":"Singh S, Malhotra V, Sarin SK. Distribution of hepatitis C genotypes in patients with chronic hepatitis C infection in India. Indian J Med Res 2004;119:145\u2013148","journal-title":"Indian J Med Res"},{"key":"9630_CR111","first-page":"326","volume":"133","author":"A Chakravarti","year":"2011","unstructured":"Chakravarti A, Dogra G, Verma V, Srivastava AP. Distribution pattern of HCV genotypes & its association with viral load. Indian J Med Res 2011;133:326\u2013331","journal-title":"Indian J Med Res"},{"issue":"4","key":"9630_CR112","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/jmv.23876","volume":"86","author":"AC Gupta","year":"2014","unstructured":"Gupta AC, Trehanpati N, Sukriti S, Hissar S, Midha V, Sood A, et al. Interleukin28b CC genotype predicts early treatment response and CT\/TT genotypes predicts non response in patients infected with HCV genotype 3. J Med Virol 2014;86(4):707\u2013712","journal-title":"J Med Virol"},{"key":"9630_CR113","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12664-014-0451-5","volume":"33","author":"A Sood","year":"2014","unstructured":"Sood A, Midha V, Goyal O, Hissar S, Sharma SK, Khanna P. Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in treatment-na\u00efve \u2018real-life\u2019 patients in India. Indian J Gastroenterol 2014;33:343\u2013349","journal-title":"Indian J Gastroenterol"},{"key":"9630_CR114","unstructured":"CTRI\/2014\/02\/004403A Phase 3b, Multi-center, randomized, open-label, study to evaluate the safety and efficacy of sofosbuvir plus ribavirin in treatment-na\u00efve adults with chronic genotype 1 or 3 hepatisis C virus infection"},{"key":"9630_CR115","unstructured":"Statistics Bureau, Ministry of Internal Affairs and Communications. Statistics Japan. http:\/\/www.stat.go.jp\/data\/jinsui\/new.htm. Accessed on 30 Mar 2014"},{"key":"9630_CR116","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/BF01694754","volume":"5","author":"H Tanaka","year":"1994","unstructured":"Tanaka H, Hiyama T, Tsukuma H, Okubo Y, Yamano H, Kitada A, et al. Prevalence of second generation antibody to hepatitis C virus among voluntary blood donors in Osaka, Japan. Cancer Causes Control. 1994;5:409\u2013413","journal-title":"Cancer Causes Control"},{"key":"9630_CR117","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000324525","volume":"54","author":"J Tanaka","year":"2011","unstructured":"Tanaka J, Koyama T, Mizui M, Uchida S, Katayama K, Matsuo J, et al. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology 2011;54:185\u2013195","journal-title":"Intervirology"},{"key":"9630_CR118","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1440-1746.2004.03399.x","volume":"19","author":"T Kanda","year":"2004","unstructured":"Kanda T, Yokosuka O, Imazeki F, Saisho H, Nagao K. Hepatitis C infection with history of tuberculosis in Japan: no association with progression of liver fibrosis. J Gastroenterol Hepatol 2004;19:717\u2013719","journal-title":"J Gastroenterol Hepatol"},{"key":"9630_CR119","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/BF02090056","volume":"39","author":"S Takano","year":"1994","unstructured":"Takano S, Omata M, Ohto M, Satomura Y. Prospective assessment of incidence of fulminant hepatitis in post-transfusion hepatitis: a study of 504 cases. Dig Dis Sci. 1994;39:28\u201332","journal-title":"Dig Dis Sci"},{"key":"9630_CR120","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/hep.510230408","volume":"23","author":"S Takano","year":"1996","unstructured":"Takano S, Nakamura K, Kawai S, Yokosuka O, Satomura Y, Omata M. Prospective assessment of donor blood screening for antibody to hepatitis C virus by first- and second-generation assays as a means of preventing posttransfusion hepatitis. Hepatology. 1996;23:708\u2013712","journal-title":"Hepatology"},{"key":"9630_CR121","first-page":"191","volume":"13","author":"K Iwamura","year":"1988","unstructured":"Iwamura K. Clinicopathological aspects of liver diseases associated with early history of tattooing. Tokai J Exp Clin Med. 1988;13:191\u2013218","journal-title":"Tokai J Exp Clin Med"},{"key":"9630_CR122","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/hepr.12066","volume":"43","author":"H Morikawa","year":"2013","unstructured":"Morikawa H, Kozuka R, Fujii H, Iwai S, Enomoto M, Tamori A, et al. Combination therapy of natural human interferon-beta and ribavirin for chronic hepatitis C patients with injection drug use. Hepatol Res 2013;43:1013\u20131019","journal-title":"Hepatol Res"},{"key":"9630_CR123","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.3748\/wjg.v12.i29.4757","volume":"12","author":"T Kogure","year":"2006","unstructured":"Kogure T, Ueno Y, Kanno N, Fukushima K, Yamagiwa Y, Nagasaki F, et al. Sustained viral response of a case of acute hepatitis C virus infection via needle-stick injury. World J Gastroenterol 2006;12:4757\u20134760","journal-title":"World J Gastroenterol"},{"key":"9630_CR124","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1872-034X.2012.00968.x","volume":"42","author":"J Murakami","year":"2012","unstructured":"Murakami J, Nagata I, Iitsuka T, Okamoto M, Kaji S, Hoshika T, et al. Risk factors for mother-to-child transmission of hepatitis C virus: maternal high viral load and fetal exposure in the birth canal. Hepatol Res 2012;42:648\u2013657","journal-title":"Hepatol Res"},{"key":"9630_CR125","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/jmv.20265","volume":"75","author":"H Nakayama","year":"2005","unstructured":"Nakayama H, Sugai Y, Ikeya S, Inoue J, Nishizawa T, Okamoto H. Molecular investigation of interspousal transmission of hepatitis C virus in two Japanese patients who acquired acute hepatitis C after 40 or 42\u00a0years of marriage. J Med Virol 2005;75:258\u2013266","journal-title":"J Med Virol"},{"key":"9630_CR126","doi-asserted-by":"publisher","first-page":"e73615","DOI":"10.1371\/journal.pone.0073615","volume":"8","author":"S Wu","year":"2013","unstructured":"Wu S, Kanda T, Nakamoto S, Jiang X, Miyamura T, Nakatani SM, et al. Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region. PLoS One 2013;8:e73615","journal-title":"PLoS One"},{"key":"9630_CR127","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1046\/j.1365-2516.1998.440595.x","volume":"4","author":"Y Fukuda","year":"1998","unstructured":"Fukuda Y, Nakano I, Katano Y, Toyoda H, Imoto M, Takamatsu J, et al. Assessment and treatment of liver disease in Japanese haemophilia patients. Haemophilia. 1998;4:595\u2013600","journal-title":"Haemophilia"},{"key":"9630_CR128","first-page":"1","volume":"5","author":"H Toyoda","year":"2014","unstructured":"Toyoda H, Kumada T, Takaguchi K, Shimada N, Tanaka J. Changes in hepatitis C virus genotype distribution in Japan. Epidemiol Infect 2014;5:1\u20135","journal-title":"Epidemiol Infect"},{"key":"9630_CR129","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399\u2013401","journal-title":"Nature"},{"key":"9630_CR130","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100\u20131104","journal-title":"Nat Genet"},{"key":"9630_CR131","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105\u20131109","journal-title":"Nat Genet"},{"key":"9630_CR132","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1099\/vir.0.029124-0","volume":"92","author":"H Ochi","year":"2011","unstructured":"Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Imamura M, et al. IL-28B predicts response to chronic hepatitis C therapy\u2014fine-mapping and replication study in Asian populations. J Gen Virol 2011;92:1071\u20131081","journal-title":"J Gen Virol"},{"key":"9630_CR133","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/BF02087547","volume":"39","author":"E Mita","year":"1994","unstructured":"Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci. 1994;39:977\u2013982","journal-title":"Dig Dis Sci"},{"key":"9630_CR134","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1159\/000080876","volume":"47","author":"O Yokosuka","year":"2004","unstructured":"Yokosuka O, Iwama S, Suzuki N, Takashi M, Hirai Y, Uchiumi K, et al. High sustained virologic response rate after interferon monotherapy in Japanese hepatitis C patients with a low HCV RNA titer and\/or HCV genotype 2. A prospective study. Intervirology 2004;47:328\u2013334","journal-title":"Intervirology"},{"key":"9630_CR135","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1478-3231.2006.01263.x","volume":"26","author":"K Fujiwara","year":"2006","unstructured":"Fujiwara K, Yokosuka O, Komine F, Moriyama M, Kato N, Yoshida H, et al. Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1. Liver Int 2006;26:520\u2013528","journal-title":"Liver Int"},{"key":"9630_CR136","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1440-1746.2007.04834.x","volume":"22","author":"M Kuboki","year":"2007","unstructured":"Kuboki M, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, et al. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. J Gastroenterol Hepatol 2007;22:645\u2013652","journal-title":"J Gastroenterol Hepatol"},{"key":"9630_CR137","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1007\/s10620-011-1750-7","volume":"56","author":"T Kanda","year":"2011","unstructured":"Kanda T, Imazeki F, Azemoto R, Yonemitsu Y, Mikami S, Kita K, et al. Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. Dig Dis Sci 2011;56:3335\u20133342","journal-title":"Dig Dis Sci"},{"key":"9630_CR138","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1111\/j.1365-2893.2011.01528.x","volume":"19","author":"N Hayashi","year":"2012","unstructured":"Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 2012;19:e134\u2013e142","journal-title":"J Viral Hepat"},{"key":"9630_CR139","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s00535-013-0875-1","volume":"49","author":"N Hayashi","year":"2014","unstructured":"Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon\/ribavirin for treatment-na\u00efve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2014;49:138\u2013147","journal-title":"J Gastroenterol"},{"key":"9630_CR140","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00535-014-0949-8","volume":"49","author":"N Izumi","year":"2014","unstructured":"Izumi N, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 2014;49:941\u2013953","journal-title":"J Gastroenterol"},{"key":"9630_CR141","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jhep.2013.02.008","volume":"59","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Bhanja S, et al. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. J Hepatol 2013;59:11\u201317","journal-title":"J Hepatol"},{"key":"9630_CR142","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.cgh.2013.09.067","volume":"12","author":"M Rodriguez-Torres","year":"2014","unstructured":"Rodriguez-Torres M, Stoehr A, Gane EJ, Serfaty L, Lawitz E, Zhou A, et al. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis. Clin Gastroenterol Hepatol 2014;12:1029\u20131037","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9630_CR143","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/liv.12254","volume":"34","author":"S Nishiguchi","year":"2014","unstructured":"Nishiguchi S, Sakai Y, Kuboki M, Tsunematsu S, Urano Y, Sakamoto W, et al. Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection. Liver Int 2014;34:78\u201388","journal-title":"Liver Int"},{"key":"9630_CR144","unstructured":"Boehringer Ingelheim. Boehringer Ingelheim\u2019s investigational faldaprevir\u00a0+\u00a0achieved viral cure in 88% of treatment-na\u00efve hepatitis C patients in Asia. https:\/\/www.boehringer-ingelheim.com\/news\/news_releases\/press_releases\/2013\/08_june_2013_hcv.html. Accessed on 30 Mar 2014"},{"issue":"881\u2013889","key":"9630_CR145","first-page":"e1","volume":"141","author":"GR Foster","year":"2011","unstructured":"Foster GR, H\u00e9zode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011;141(881\u2013889):e1","journal-title":"Gastroenterology"},{"key":"9630_CR146","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014;59:2083\u20132091","journal-title":"Hepatology"},{"key":"9630_CR147","unstructured":"Mizokami M, Takehara T, Yokosuka O, Sakamoto N, Korenaga M, Mochizuki H, et al. 100% SVR4 in Japanese patients with chronic genotype 1 hepatitis C virus infection receiving ledipasvir\/sofosbuvir fixed dose combination for 12 weeks: results from a Multicenter Phase 3 Study. Hepatology 2014;60 Suppl S1:1130A"},{"key":"9630_CR148","unstructured":"ClinicalTrials.gov. Study to Evaluate the Efficacy and Safety of for 24 wks [33] (ABT-450\/r\/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection (GIFT I). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02023099?term=AbbVie+and+Hepatitis+C&recr=Open&no_unk=Y&rank=6. Accessed on 30 Mar 2014"},{"key":"9630_CR149","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.26719\/2010.16.Supp.15","volume":"16","author":"H Qureshi","year":"2010","unstructured":"Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HUR. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East Mediterr Health J 2010;16:S15\u2013S23","journal-title":"East Mediterr Health J"},{"issue":"5","key":"9630_CR150","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1365-2893.2009.01230.x","volume":"17","author":"NZ Janjua","year":"2010","unstructured":"Janjua NZ, Hamza HB, Islam M, Tirmizi SF, Siddiqui A, Jafri W, et al. Health care risk factors among women and personal behaviors among men explain the high prevalence of hepatitis C virus infection in Karachi, Pakistan. J Viral Hepat 2010;17(5):317\u2013326","journal-title":"J Viral Hepat"},{"key":"9630_CR151","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s12072-012-9417-9","volume":"7","author":"B Ahmed","year":"2013","unstructured":"Ahmed B, Ali T, Qureshi H, Hamid S. Population-attributable estimates for risk factors associated with hepatitis B and C: policy implications for Pakistan and other South Asian countries. Hepatol Int 2013;7:500\u2013507","journal-title":"Hepatol Int"},{"key":"9630_CR152","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S1201-9712(02)90160-8","volume":"6","author":"T Moatter","year":"2002","unstructured":"Moatter T, Hussainy AS, Hamid S, Ahmad Z, Siddiqui S. Comparative analysis of viral titers and histologic features of Pakistani patients infected with hepatitis C virus type 3. Int J Infect Dis 2002;6:272\u2013275","journal-title":"Int J Infect Dis"},{"key":"9630_CR153","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/jmv.21466","volume":"81","author":"A Khan","year":"2009","unstructured":"Khan A, Tanaka Y, Azam Z, Abbas Z, Kurbanov F, Saleem U, et al. Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan. J Med Virol 2009;81:1189\u20131197","journal-title":"J Med Virol"},{"key":"9630_CR154","first-page":"1671","volume":"29","author":"K Mumtaz","year":"2008","unstructured":"Mumtaz K, Hamid SS, Moatter T, Abid S, Shah HA, Jafri W. Distribution of hepatitis C virus genotypes and its response to treatment in Pakistani patients. Saudi Med J 2008;29:1671\u20131673","journal-title":"Saudi Med J"},{"key":"9630_CR155","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0929-6646(09)60231-X","volume":"106","author":"CH Chen","year":"2007","unstructured":"Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007;106:148\u2013155","journal-title":"J Formos Med Assoc"},{"key":"9630_CR156","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000087271","volume":"49","author":"WL Chuang","year":"2006","unstructured":"Chuang WL, Yu ML, Dai CY, Chang WY. Treatment of chronic hepatitis C in southern Taiwan. Intervirology 2006;49:99\u2013106","journal-title":"Intervirology"},{"key":"9630_CR157","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1607-551X(10)70073-5","volume":"26","author":"JF Yang","year":"2010","unstructured":"Yang JF, Lin CI, Huang JF, Dai CY, Lin WY, Ho CK, et al. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci 2010;26:461\u2013469","journal-title":"Kaohsiung J Med Sci"},{"key":"9630_CR158","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.trstmh.2003.10.013","volume":"98","author":"PL Lee","year":"2004","unstructured":"Lee PL, Wang JH, Tung HD, Lee CM, Lu SN. A higher than expected recovery rate from hepatitis C infection amongst adolescents: a community study in a hepatitis C-endemic township in Taiwan. Trans R Soc Trop Med Hyg 2004;98:367\u2013372","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"9630_CR159","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.trstmh.2008.05.018","volume":"102","author":"CF Huang","year":"2008","unstructured":"Huang CF, Huang JF, Dai CY, Yu ML, Lu SN, Hsieh MY, et al. Changing prevalence of hepatitis C virus infection among teenagers in an endemic area in Taiwan. Trans R Soc Trop Med Hyg 2008;102:929\u2013934","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"9630_CR160","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1017\/S0950268801006148","volume":"127","author":"JF Huang","year":"2001","unstructured":"Huang JF, Lu SN, Chue PY, Lee CM, Yu ML, Chuang WL, et al. Hepatitis C virus infection among teenagers in an endemic township in Taiwan: epidemiological and clinical follow-up studies. Epidemiol Infect 2001;127:485\u2013492","journal-title":"Epidemiol Infect"},{"key":"9630_CR161","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1046\/j.1440-1746.2000.02359.x","volume":"15","author":"ML Yu","year":"2000","unstructured":"Yu ML, Chuang WL, Wang LY, Dai CY, Chiou SS, Sung MH, et al. Status and natural course of GB virus C\/hepatitis G virus infection among high-risk groups and volunteer blood donors in Taiwan. J Gastroenterol Hepatol 2000;15:1404\u20131410","journal-title":"J Gastroenterol Hepatol"},{"key":"9630_CR162","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000100506","volume":"74","author":"SS Chiou","year":"2006","unstructured":"Chiou SS, Huang JF, Chang TT, Hsieh MY, Dai CY, Yu ML, et al. SEN and hepatitis virus infections in nontransfused children and pediatric thalassemia patients with multiple transfusions in Taiwan. Digestion 2006;74:208\u2013214","journal-title":"Digestion"},{"key":"9630_CR163","doi-asserted-by":"publisher","first-page":"436","DOI":"10.7150\/ijms.8265","volume":"11","author":"JM Chang","year":"2014","unstructured":"Chang JM, Huang CF, Chen SC, Dai CY, Yeh ML, Huang JF, et al. Discrepancy between serological and virological analysis of viral hepatitis in hemodialysis patients. Int J Med Sci 2014;11:436\u2013441","journal-title":"Int J Med Sci"},{"key":"9630_CR164","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jhep.2013.09.023","volume":"60","author":"ML Yu","year":"2014","unstructured":"Yu ML, Dai CY, Huang CF, Lee JJ, Yeh ML, Yeh SM, et al. High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients. J Hepatol 2014;60:253\u2013259","journal-title":"J Hepatol"},{"key":"9630_CR165","doi-asserted-by":"publisher","first-page":"e94791","DOI":"10.1371\/journal.pone.0094791","volume":"9","author":"MH Hsieh","year":"2014","unstructured":"Hsieh MH, Tsai JJ, Hsieh MY, Huang CF, Yeh ML, Yang JF, et al. Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection. PLoS One 2014;9:e94791","journal-title":"PLoS One"},{"key":"9630_CR166","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1440-1746.2009.05789.x","volume":"24","author":"ML Yu","year":"2009","unstructured":"Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009;24:336\u2013345","journal-title":"J Gastroenterol Hepatol"},{"key":"9630_CR167","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/jmv.2001","volume":"65","author":"ML Yu","year":"2001","unstructured":"Yu ML, Chuang WL, Chen SC, Dai CY, Hou C, Wang JH, et al. Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. J Med Virol 2001;65:58\u201365","journal-title":"J Med Virol"},{"key":"9630_CR168","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/hep.24049","volume":"53","author":"CF Huang","year":"2011","unstructured":"Huang CF, Dai CY, Huang JF, Chuang WL, Yu ML. Linkage of the hepatitis C virus genotype and interleukin-28B genetic polymorphisms in Asian patients. Hepatology 2011;53:367\u2013368","journal-title":"Hepatology"},{"key":"9630_CR169","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jhep.2011.03.029","volume":"56","author":"CF Huang","year":"2012","unstructured":"Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, et al. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24\u00a0weeks peginterferon\/ribavirin. J Hepatol 2012;56:34\u201340","journal-title":"J Hepatol"},{"key":"9630_CR170","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hep.23976","volume":"53","author":"ML Yu","year":"2011","unstructured":"Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, Lin ZY, et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011;53:7\u201313","journal-title":"Hepatology"},{"key":"9630_CR171","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1089\/jir.1995.15.611","volume":"15","author":"SJ Hwang","year":"1995","unstructured":"Hwang SJ, Chan CY, Lu RH, Wu JC, Lee SD. Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C. J Interferon Cytokine Res. 1995;15:611\u2013616","journal-title":"J Interferon Cytokine Res"},{"key":"9630_CR172","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/gast.1996.v111.pm8898645","volume":"111","author":"MY Lai","year":"1996","unstructured":"Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology. 1996;111:1307\u20131312","journal-title":"Gastroenterology"},{"key":"9630_CR173","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1471-2334-5-27","volume":"5","author":"ML Yu","year":"2005","unstructured":"Yu ML, Dai CY, Chen SC, Lee LP, Hsieh MY, Lin ZY, et al. High versus standard doses interferon-alpha in the treatment of naive chronic hepatitis C patients in Taiwan: a 10-year cohort study. BMC Infect Dis 2005;5:27","journal-title":"BMC Infect Dis"},{"key":"9630_CR174","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1136\/gut.2006.102558","volume":"56","author":"ML Yu","year":"2007","unstructured":"Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al. A randomised study of peginterferon and ribavirin for 16 versus 24\u00a0weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553\u2013559","journal-title":"Gut"},{"key":"9630_CR175","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/hep.22319","volume":"47","author":"ML Yu","year":"2008","unstructured":"Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008;47:1884\u20131893","journal-title":"Hepatology"},{"key":"9630_CR176","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1086\/592579","volume":"47","author":"CH Liu","year":"2008","unstructured":"Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008;47:1260\u20131269","journal-title":"Clin Infect Dis"},{"key":"9630_CR177","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.antiviral.2004.01.002","volume":"63","author":"ML Yu","year":"2004","unstructured":"Yu ML, Dai CY, Chen SC, Lee LP, Huang JF, Lin ZY, et al. A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors. Antiviral Res 2004;63:25\u201332","journal-title":"Antiviral Res"},{"key":"9630_CR178","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/hep.22319","volume":"47","author":"ML Yu","year":"2008","unstructured":"Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008;47:1884\u20131893","journal-title":"Hepatology"},{"key":"9630_CR179","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1365-2893.2005.00590.x","volume":"12","author":"SD Lee","year":"2005","unstructured":"Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005;12:283\u2013291","journal-title":"J Viral Hepat"},{"key":"9630_CR180","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1440-1746.2005.03791.x","volume":"20","author":"CH Hung","year":"2005","unstructured":"Hung CH, Lee CM, Lu SN, Wang JH, Tung HD, Chen CH, et al. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol 2005;20:727\u2013732","journal-title":"J Gastroenterol Hepatol"},{"key":"9630_CR181","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/j.1478-3231.2006.01358a.x","volume":"26","author":"ML Yu","year":"2006","unstructured":"Yu ML, Dai CY, Lee LP, Hou NJ, Hsieh MY, Huang JF, et al. A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. Liver Int 2006;26:1187\u20131195","journal-title":"Liver Int"},{"key":"9630_CR182","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/jgh.12211","volume":"28","author":"CF Huang","year":"2013","unstructured":"Huang CF, Yeh ML, Hsieh MH, Hsieh MY, Lin ZY, Chen SC, et al. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin. J Gastroenterol Hepatol 2013;28:1515\u20131520","journal-title":"J Gastroenterol Hepatol"},{"key":"9630_CR183","doi-asserted-by":"publisher","first-page":"e58882","DOI":"10.1371\/journal.pone.0058882","volume":"8","author":"CF Huang","year":"2013","unstructured":"Huang CF, Dai CY, Yeh ML, Huang JF, Huang CI, Hsieh MY, et al. Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients. PLoS One 2013;8:e58882","journal-title":"PLoS One"},{"key":"9630_CR184","unstructured":"Boehringer Ingelheim. Boehringer Ingelheim\u2019s investigational faldaprevir\u00a0+\u00a0achieved viral cure in 88% of treatment-na\u00efve hepatitis C patients in Asia. https:\/\/www.boehringer-ingelheim.com\/news\/news_releases\/press_releases\/2013\/08_june_2013_hcv.html. Accessed on 27 June 2014"},{"key":"9630_CR185","unstructured":"Boehringer Ingelheim. Boehringer Ingelheim Statement on Hepatitis C drug development. https:\/\/www.boehringer-ingelheim.com\/news\/news_releases\/press_releases\/2014\/20_june_2014_hepatitis.html. Accessed on 27 June 2014"},{"key":"9630_CR186","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014;384:1597\u20131605","journal-title":"Lancet"},{"key":"9630_CR187","unstructured":"A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01749150?term=ritonavir+AND+Taiwan&rank=2. Accessed on 30 June 2014"},{"key":"9630_CR188","unstructured":"A Phase 3 Study of a Daclatasvir\/Asunaprevir\/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1 (UNITY 4). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02170727?term=BMS-791325&rank=19. Accessed on 30 June 2014"},{"key":"9630_CR189","unstructured":"Efficacy and Safety of Sofosbuvir Plus Ribavirin in Subjects With Chronic HCV Infection. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02021643?term=sofosbuvir+AND+Taiwan&rank=1. Accessed on 30 June 2014"},{"key":"9630_CR190","unstructured":"Efficacy and safety of ledipasvir\/sofosbuvir fixed-dose combination in Korean and Taiwanese participants with chronic genotype 1 HCV infection. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02021656?term=sofosbuvir+AND+Taiwan&rank=2. Accessed on 30 June 2014"},{"key":"9630_CR191","unstructured":"Study of efficacy and safety of MK-5172\/MK-8742 combination regimen for treatment-na\u00efve participants with chronic hepatitis C virus genotypes 1, 4, 5, and 6 (MK-5172-060). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02105467?term=MK-5172-060&rank=1. Accessed on 30 June 2014"},{"key":"9630_CR192","unstructured":"An efficacy and safety study of MK-5172\u00a0+\u00a0MK-8742 in the treatment of chronic hepatitis C virus genotype 1, 4, 5 or 6 infection in treatment-na\u00efve participants who are on opiate substitution therapy (MK-5172-062) (C-COSTAR). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02105688?term=MK-5172-062&rank=1. Accessed on 30 June 2014"},{"key":"9630_CR193","unstructured":"Data of Turkish Statistical Institute in 2011. http:\/\/www.turkstat.gov.tr. Accessed on 27 Oct 2014"},{"key":"9630_CR194","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ijid.2008.07.005","volume":"13","author":"FZ Akcam","year":"2009","unstructured":"Akcam FZ, Uskun E, Avsar K, Songur Y. Hepatitis B virus and hepatitis C virus seroprevalence in rural areas of the southwestern region of Turkey. Int J Infect Dis 2009;13:274\u2013284","journal-title":"Int J Infect Dis"},{"key":"9630_CR195","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10654-006-0001-2","volume":"21","author":"E Gurol","year":"2006","unstructured":"Gurol E, Saban C, Oral O, Cigdem A, Armagan A. Trends in hepatitis B and hepatitis C virus among blood donors over 16\u00a0years in Turkey. Eur J Epidemiol 2006;21:299\u2013305","journal-title":"Eur J Epidemiol"},{"key":"9630_CR196","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10620-006-3139-6","volume":"51","author":"C Karaca","year":"2006","unstructured":"Karaca C, Cakalo\u011flu Y, Demir K, Ozdil S, Kaymako\u011flu S, Badur S, et al. Risk factors for the transmission of hepatitis C virus infection in the Turkish population. Dig Dis Sci 2006;51:365\u2013369","journal-title":"Dig Dis Sci"},{"key":"9630_CR197","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1007\/s00705-004-0363-2","volume":"149","author":"AM Bozdayi","year":"2004","unstructured":"Bozdayi AM, Aslan N, Bozdayi G, T\u00fcrkyilmaz AR, Sengezer T, Wend U, et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol 2004;149:2115\u20132129","journal-title":"Arch Virol"},{"key":"9630_CR198","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ijid.2007.07.003","volume":"12","author":"I Altuglu","year":"2008","unstructured":"Altuglu I, Soyler I, Ozacar T, Erensoy S. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. Int J Infect Dis 2008;12:239\u2013244","journal-title":"Int J Infect Dis"},{"key":"9630_CR199","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1097\/MEG.0b013e3283554c41","volume":"24","author":"H Simsek","year":"2012","unstructured":"Simsek H, Alp A, Yilmaz B, Balaban YH, Altun B, Uzun O, et al. The genotype frequencies of IL28B polymorphisms (rs12979860, rs8099917) among Turkish patients with hepatitis C. Eur J Gastroenterol Hepatol 2012;24:1113\u20131115","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"9630_CR200","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1023\/A:1018854424403","volume":"42","author":"H Senturk","year":"1997","unstructured":"Senturk H, Uzunalimoglu O, Batur Y, Simsek I, Mert A, Ozbay G, et al. Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis. Dig Dis Sci. 1997;42:1438\u20131444","journal-title":"Dig Dis Sci"},{"key":"9630_CR201","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/030006059602400117","volume":"24","author":"H Simsek","year":"1996","unstructured":"Simsek H, Tatar G, Savas C, Telatar H. Treatment of chronic hepatitis C infection with interferon alpha-2a in a Turkish population. J Int Med Res. 1996;24:132\u2013137","journal-title":"J Int Med Res"},{"key":"9630_CR202","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00005176-200202000-00018","volume":"34","author":"DOD S\u00fco\u011flu","year":"2002","unstructured":"S\u00fco\u011flu DOD, Elkabes B, S\u00f6k\u00fcc\u00fc S, Saner G. Does interferon and ribavirin combination therapy increase the rate of treatment response in children withhepatitis C? J Pediatr Gastroenterol Nutr 2002;34:199\u2013206","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"9630_CR203","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1023\/A:1023725014751","volume":"48","author":"H Senturk","year":"2003","unstructured":"Senturk H, Ersoz G, Ozaras R, Kaymakoglu S, Bozkaya H, Akdogan M, et al. Interferon-alpha2b induction treatment with or without ribavirin in chronic\u00a0hepatitis C: a multicenter, randomized, controlled trial. Dig Dis Sci 2003;48(6):1124\u20131129","journal-title":"Dig Dis Sci"},{"key":"9630_CR204","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s15010-008-7134-z","volume":"36","author":"SC Akhan","year":"2008","unstructured":"Akhan SC, Kalender B, Ruzgar M. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection. Infection 2008;36:341\u2013344","journal-title":"Infection"},{"key":"9630_CR205","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.5754\/hge10625","volume":"58","author":"S Coban","year":"2011","unstructured":"Coban S, Idilman R, Erden E, T\u00fcz\u00fcn A. Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C. Hepatogastroenterology 2011;58:1301\u20131306","journal-title":"Hepatogastroenterology"},{"key":"9630_CR206","first-page":"94","volume":"17","author":"N Yenice","year":"2006","unstructured":"Yenice N, Mehtap O, G\u00fcmrah M, Arican N. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol 2006;17:94\u201398","journal-title":"Turk J Gastroenterol"},{"key":"9630_CR207","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/liv.12108","volume":"33","author":"Y Kim do","year":"2013","unstructured":"Kim do Y, Kim IH, Jeong SH, Cho YK, Lee JH, Jin YJ, et al. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int 2013;33:586\u2013594","journal-title":"Liver Int"},{"key":"9630_CR208","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3904\/kjim.2012.27.2.121","volume":"27","author":"A Jazag","year":"2012","unstructured":"Jazag A, Puntsagdulam N, Chinburen J. Status quo of chronic liver diseases, including hepatocellular carcinoma, in Mongolia. Korean J Intern Med 2012;27:121\u2013127","journal-title":"Korean J Intern Med"},{"key":"9630_CR209","first-page":"609","volume":"42","author":"N Chimparlee","year":"2011","unstructured":"Chimparlee N, Oota S, Phikulsod S, Tangkijvanich P, Poovorawan Y. Hepatitis B and hepatitis C virus in Thai blood donors. Southeast Asian J Trop Med Public Health 2011;42:609\u2013615","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"9630_CR210","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/1545109712453939","volume":"11","author":"L Sereno","year":"2012","unstructured":"Sereno L, Mesquita F, Kato M, Jacka D, Nguyen TT, Nguyen TN. Epidemiology, responses, and way forward: the silent epidemic of viral hepatitis and HIV coinfection in Vietnam. J Int Assoc Physicians AIDS Care (Chic) 2012;11:311\u2013320","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"key":"9630_CR211","first-page":"674","volume":"18","author":"M Khodabandehloo","year":"2013","unstructured":"Khodabandehloo M, Roshani D, Sayehmiri K. Prevalence and trend of hepatitis C virus infection among blood donors in Iran: a systematic review and meta-analysis. J Res Med Sci 2013;18:674\u2013682","journal-title":"J Res Med Sci"},{"key":"9630_CR212","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s12072-012-9342-y","volume":"6","author":"M Omata","year":"2012","unstructured":"Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409\u2013435","journal-title":"Hepatol Int"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-015-9630-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9630-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T19:49:14Z","timestamp":1717876154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-015-9630-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,5]]},"references-count":212,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["9630"],"URL":"https:\/\/doi.org\/10.1007\/s12072-015-9630-4","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,5]]},"assertion":[{"value":"17 November 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}